1. Inhibition of colony stimulating factor-1 receptor (CSF-1R) as a potential therapeutic strategy for neurodegenerative diseases: opportunities and challenges.
- Author
-
Han J, Chitu V, Stanley ER, Wszolek ZK, Karrenbauer VD, and Harris RA
- Subjects
- Animals, Colony-Stimulating Factors pharmacology, Colony-Stimulating Factors therapeutic use, Microglia metabolism, Alzheimer Disease drug therapy, Neurodegenerative Diseases drug therapy, Neurodegenerative Diseases metabolism, Parkinson Disease drug therapy
- Abstract
Microglia are specialized dynamic immune cells in the central nervous system (CNS) that plays a crucial role in brain homeostasis and in disease states. Persistent neuroinflammation is considered a hallmark of many neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and primary progressive multiple sclerosis (MS). Colony stimulating factor 1-receptor (CSF-1R) is predominantly expressed on microglia and its expression is significantly increased in neurodegenerative diseases. Cumulative findings have indicated that CSF-1R inhibitors can have beneficial effects in preclinical neurodegenerative disease models. Research using CSF-1R inhibitors has now been extended into non-human primates and humans. This review article summarizes the most recent advances using CSF-1R inhibitors in different neurodegenerative conditions including AD, PD, HD, ALS and MS. Potential challenges for translating these findings into clinical practice are presented., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF